© Reuters.
NEW YORK (Reuters) – A federal appeals court on Tuesday revived a lawsuit by a whistleblower who accused McKesson (NYSE:) of providing drug pricing tools to doctors to induce them to purchase drugs from the company.
The decision by the 2nd U.S. Circuit Court of Appeals in Manhattan restores claims by Adam Hart, a former McKesson business development executive.
Q2: 2025-09-03 Earnings AbstractEPS of $2.91 beats by $0.13 | Income of $10.24B (9.77% Y/Y) beats by $98.41MThis text was written...
Liquidation normal merchandise (we wish to name it “gen merch”) is without doubt one of the most versatile kinds of...
folks like to complain about how dangerous issues are, however let’s be clear they’ve been approach worse Through HistoryinMemes Worst...
Free inventory promotions are one of many best methods to begin investing with out committing a big sum of cash...
U.S. President Donald Trump waves from the roof of the West Wing of the White Home as he takes a...
Get the latest news and follow the coverage of Investing, World News, Stocks, Market Analysis, Business & Financial News, and more from the top trusted sources.
